BioCryst Pharmaceuticals | BCRX - Equity Capital And Reserves


BioCryst Pharmaceuticals reported $-454.29M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Chugai Pharma JPY 2.03T 135.62B Dec/2025
Daiichi Sankyo JPY 1.7T 38.53B Jun/2026
DBV Technologies USD 160.4M 47.5M Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novavax USD -190.71M 45.94M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026